Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory approvals and commercial launches across oncology, neuroscience, immunology, and diagnostics, reinforcing its strategy of science-led, patient-centric innovation. The 2025 milestones reflect Roche’s focus on precision medicine, high-value specialty therapies, and diagnostic integration, setting the stage for continued growth in 2026.
Oncology Portfolio: Precision and Next-Generation Innovation
Tecentriq® — Immuno-Oncology
Conditions: Non-small cell lung cancer, triple-negative breast cancer, and other solid tumors
In 2025, Tecentriq gained new label expansions and launched in additional markets, strengthening Roche’s checkpoint inhibitor franchise.
Strategic Impact:
Tecentriq’s approvals support Roche’s leadership in immuno-oncology and expand access to innovative cancer care worldwide.
Polivy® — B-Cell Malignancies
Condition: Diffuse large B-cell lymphoma (DLBCL)
Polivy advanced through new indications and commercial rollouts in 2025, reinforcing Roche’s position in targeted oncology therapies.
Strategic Impact:
Polivy diversifies Roche’s oncology portfolio while supporting multi-billion-dollar growth trajectories in hematology.
Neuroscience Portfolio: Targeting Unmet Needs
Ocrevus® — Multiple Sclerosis
Condition: Relapsing and primary progressive MS
Ocrevus maintained strong uptake in 2025 following global launch expansion and label enhancements, solidifying Roche’s neuroscience leadership.
Vabysmo® — Retinal Disorders
Condition: Neovascular age-related macular degeneration and diabetic macular edema
Roche expanded Vabysmo’s commercial availability in 2025, supporting high-value ophthalmology growth.
Strategic Impact:
These launches enhance Roche’s specialty CNS and ophthalmology footprint, providing sustainable revenue streams outside oncology.
Diagnostics and AI-Enabled Healthcare
Diagnostics Solutions
Roche Diagnostics continued 2025 expansion with AI-powered platforms for oncology, infectious disease, and personalized medicine, including:
- AI-driven pathology and imaging analytics
- Precision oncology companion diagnostics
- Real-world evidence integration for clinical decision support
Strategic Impact:
Diagnostics and AI integration strengthen Roche’s differentiated care ecosystem, linking therapy and testing for better patient outcomes.
Commercial and Strategic Execution
Across 2025, Roche leveraged:
- Targeted launches and market access initiatives
- AI- and data-driven R&D and commercial planning
- Partnerships with biotech and tech players to accelerate innovation
Strategic Impact:
This execution enhances launch efficiency, trial productivity, and portfolio prioritization in key therapeutic areas.
Looking Ahead: 2026 and Beyond
Roche enters 2026 with:
- A strong oncology and immuno-oncology pipeline
- Growing CNS and ophthalmology franchises
- AI-enabled diagnostic platforms supporting precision healthcare expansion
The company’s 2025 approvals and launches provide the foundation for durable growth, innovation leadership, and patient-centric impact in 2026.
Conclusion
Roche’s 2025 achievements reflect a clear strategy of science-driven, specialty-focused innovation. By integrating precision medicine, AI-enabled diagnostics, and targeted therapies, Roche is positioned to deliver sustained growth and strengthen its leadership across oncology, neuroscience, and diagnostics well into 2026.
By